In support of a diabetogenic role for the eNAMPT-monomer, eNAMPT-Ab administration reduced blood glucose and insulin levels (Fig. 2a–c) and corrected impaired glucose tolerance (IGT) in HFD-fed mice (Fig. 2d–f). Here, INS is linked to Impaired glucose tolerance.